 Connection
Michael Kahn to Cisplatin
This is a "connection" page, showing publications Michael Kahn has written about Cisplatin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.139 |
|
|
|
-
Chan KC, Chan LS, Ip JC, Lo C, Yip TT, Ngan RK, Wong RN, Lo KW, Ng WT, Lee AW, Tsao GS, Kahn M, Lung ML, Mak NK. Therapeutic targeting of CBP/ß-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Sci Rep. 2015 Apr 21; 5:9979.
Score: 0.101
-
Belur Nagaraj A, Knarr M, Sekhar S, Connor RS, Joseph P, Kovalenko O, Fleming A, Surti A, Nurmemmedov E, Beltrame L, Marchini S, Kahn M, DiFeo A. The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer. Cancer Res. 2021 04 15; 81(8):2044-2055.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|